Literature DB >> 266208

Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

D T Fearon, K F Austen.   

Abstract

The surface of zymosan (Zy), by affording a protected microenvironment for C3b and the amplification convertase stabilized by properdin, P,C3b,Bb, shifts the alternative complement pathway from slow fluid phase turnover to the amplification phase of its expression. This mode of activation is in contradistinction to that of the classical pathway, which follows conversion of a proenzyme, Cl, to its active form, C1. Under conditions in which the control proteins, C3b inactivator (C3bINA) and beta1H, completely, inactivated C3b on the sheep erythrocyte intermediate, EAC4b,3b, the activity of C3b bound to Zy,ZyC3b, was diminished by only one-third. Further, when ZyC3b was converted to ZyC3b,Bb,P there was an additional point of deregulation in that the convertase was resistant to beta1H-mediated decay-dissociation while P,C3b,Bb on the sheep erythrocyte exhibited the usual susceptibility to beta1H. That Zy alone could indeed promote rapid C3 cleavage by the alternative pathway through assembly and protection of the amplification convertase on its surface was demonstrated with a mixture of alternative pathway proteins, C3,B,D,P, C3bINA, and beta1H, that had each been purified to homogeneity. Interaction of these proteins at one-tenth their relative serum concentrations with Zy permitted low-grade inactivation of C3 and B to advance to the level of amplification after a 15 min lag period. Because the reaction of the purified proteins proceeded spontaneously when either regulatory protein was deleted, the effect of Zy was attributed to deregulation rather than to conversion of one of the proteins to a specific initiating state. The alternative pathway, through the normal presence of D, interacts with a microbial surface, such as Zy, to amplify deposition of C3b by circumvention of endogenous regulatory mechanisms, thereby augmenting host defense.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 266208      PMCID: PMC430857          DOI: 10.1073/pnas.74.4.1683

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

2.  The C3-activator system: an alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

3.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

4.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

5.  The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution.

Authors:  W P Kolb; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1973-08-01       Impact factor: 14.307

6.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

7.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

8.  Chromatographic resolution of the first component of human complement into three activities.

Authors:  I H LEPOW; G B NAFF; E W TODD; J PENSKY; C F HINZ
Journal:  J Exp Med       Date:  1963-06-01       Impact factor: 14.307

9.  Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.

Authors:  R D Schreiber; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  109 in total

1.  Limited tryptic cleavage of complement factor H abrogates recognition of sialic acid-containing surfaces by the alternative pathway of complement.

Authors:  V Koistinen
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

Review 2.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

3.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

4.  Biography of Douglas T. Fearon.

Authors:  Regina Nuzzo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-17       Impact factor: 11.205

5.  Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in Gonococci.

Authors:  Sunita Gulati; Andrew Cox; Lisa A Lewis; Frank St Michael; Jianjun Li; Ryan Boden; Sanjay Ram; Peter A Rice
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

6.  The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.

Authors:  Guillermo Madico; Jo Anne Welsch; Lisa A Lewis; Anne McNaughton; David H Perlman; Catherine E Costello; Jutamas Ngampasutadol; Ulrich Vogel; Dan M Granoff; Sanjay Ram
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

7.  Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H.

Authors:  M K Pangburn
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

8.  Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin.

Authors:  Jutamas Shaughnessy; Lisa A Lewis; Hanna Jarva; Sanjay Ram
Journal:  Infect Immun       Date:  2009-03-09       Impact factor: 3.441

9.  Isolation and characterization of rat complement factor B and its interaction with cell-bound human C3.

Authors:  M R Daha; L A van Es
Journal:  Immunology       Date:  1980-12       Impact factor: 7.397

10.  Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490.

Authors:  Petya Dimitrova; Valeriya Gyurkovska; Irina Shalova; Luciano Saso; Nina Ivanovska
Journal:  J Inflamm (Lond)       Date:  2009-05-05       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.